ICAD - iCAD, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.40
+0.01 (+0.29%)
At close: 3:56PM EDT
Stock chart is not supported by your current browser
Previous Close3.39
Open3.45
Bid2.85 x 2500
Ask4.25 x 2000
Day's Range3.38 - 3.53
52 Week Range2.93 - 6.07
Volume15,678
Avg. Volume34,222
Market Cap56.452M
Beta0.74
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research18 days ago

    ICAD: Q4 2017 Results: Tomo Seeing “Strong Demand”. Plug Pulled on Unprofitable Skin Subscription Biz

    Revenue, particularly in the Detection segment, continued to impress with very strong sales of the tomo (2D and 3D) products pushing total revenue up by 14% yoy. Detection product sales, up 100% yoy (pro-forma for ex-MRI), turned in the best quarter since Q3 2011 (when ICAD was still direct-selling MRI software) and crushed our number by 25%. While Q4 is typically ICAD’s strongest, the apparent accelerating adoption of the ‘legacy’ 2D and first-gen 3D tomo (GE-only) applications is obviously encouraging, particularly given the near-term launch of ICAD’s next-gen software.

  • Thomson Reuters StreetEvents29 days ago

    Edited Transcript of ICAD earnings conference call or presentation 22-Mar-18 8:30pm GMT

    Q4 2017 ICAD Inc Earnings Call

  • InvestorPlace29 days ago

    3 Stocks to Watch on Friday: At Home Group Inc (HOME), HTG Molecular Diagnostics Inc (HTGM) and iCAD Inc (ICAD)

    The Dow Jones Industrial Average dropped more than 700 points on a down day for U.S. equities in which President Donald Trump announced tariffs on international imports from China. The index fell 2.9% Thursday, while the S&P 500 Index fell 2.5% and the Nasdaq Composite fell 2.4%.

  • Zacks Small Cap Research4 months ago

    ICAD: Study Shows IORT Superior To EBRT in Quality of Life, Cost

    By Brian Marckx, CFA NASDAQ:ICAD Decision-Tree Analysis of Published Studies Indicates IORT Superior To EBRT in QoL, Cost:   A study which was recently published in Cost Effectiveness and Resource Allocation ...

  • Are iCAD Inc’s (ICAD) Interest Costs Too High?
    Simply Wall St.5 months ago

    Are iCAD Inc’s (ICAD) Interest Costs Too High?

    While small-cap stocks, such as iCAD Inc (NASDAQ:ICAD) with its market cap of USD $58.45M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of ICAD earnings conference call or presentation 8-Nov-17 9:30pm GMT

    Q3 2017 ICAD Inc Earnings Call

  • Zacks Small Cap Research5 months ago

    ICAD: Q3 Detection and Therapy Results Solid. Tomo Growth To Accelerate

    By Brian Marckx, CFA NASDAQ:ICAD Q3 2017 Results:  Revenue Dead-On With Our Estimate. Solid Results From Both Detection and Therapy… iCAD (NASDAQ:ICAD) reported Q3 financial results for their third quarter ...

  • Capital Cube7 months ago

    ETFs with exposure to iCAD, Inc. : September 6, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to iCAD, Inc. Here are 5 ETFs with the largest exposure to ICAD-US. Comparing the performance and risk of iCAD, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • iCAD, Inc. :ICAD-US: Earnings Analysis: Q2, 2017 By the Numbers : August 31, 2017
    Capital Cube8 months ago

    iCAD, Inc. :ICAD-US: Earnings Analysis: Q2, 2017 By the Numbers : August 31, 2017

    Categories: Yahoo FinanceGet free summary analysis iCAD, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of iCAD, Inc. – Royal Philips NV Sponsored ADR, Hologic, Inc., General Electric Company, Varian Medical Systems, Inc. and Digirad Corporation (PHG-US, HOLX-US, GE-US, VAR-US and DRAD-US) that have also ... Read more (Read more...)

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of ICAD earnings conference call or presentation 8-Aug-17 8:30pm GMT

    Q2 2017 ICAD Inc Earnings Call

  • Zacks Small Cap Research8 months ago

    ICAD: A Look Behind Q2 Numbers. U.S. Tomo Launch Encouraging

    By Brian Marckx, CFA NASDAQ:ICAD Q2 2017 Results:  Results Much More Solid Than Numbers Suggest. U.S. Tomo Launch Encouraging iCAD (NASDAQ:ICAD) reported results for their second quarter ending June 30th. ...

  • iCAD, Inc. :ICAD-US: Earnings Analysis: Q1, 2017 By the Numbers : May 25, 2017
    Capital Cube11 months ago

    iCAD, Inc. :ICAD-US: Earnings Analysis: Q1, 2017 By the Numbers : May 25, 2017

    Categories: Yahoo FinanceGet free summary analysis iCAD, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of iCAD, Inc. – Fonar Corporation, Royal Philips NV Sponsored ADR, Hologic, Inc., General Electric Company, Varian Medical Systems, Inc. and Digirad Corporation (FONR-US, PHG-US, HOLX-US, GE-US, VAR-US and DRAD-US) ... Read more (Read more...)

  • Zacks Small Cap Research11 months ago

    ICAD: Q1: Strong Detection Offsets Weakness in NMSC Revenue

    Relative to our estimates, Q1 Detection revenue was about 20% better which more than offset a 7% miss to our Therapy number – the net result was a 9% beat to our total revenue estimate.  Detection was the clear highlight with revenue up 14% yoy – but excluding MRI revenues (i.e. Strength in Detection was attributed to 3D tomo sales in Europe – management noted 7 or 8 systems were sold in Q1 – as well as from “several very large (2D) tenders.”  Management mentioned that Q1 set a new record in terms of international CAD orders.  We note that since ordering patterns can be somewhat lumpy, we have not carried that level of revenue through to our Q2 number – but we also note that management indicated interest in 3D tomo in Europe continues to solidify and, as such, we think it is reasonable to expect that product will to continue to gain traction.

  • Thomson Reuters StreetEventslast year

    Edited Transcript of ICAD earnings conference call or presentation 2-May-17 8:30pm GMT

    Q1 2017 ICAD Inc Earnings Call

  • Zacks Small Cap Researchlast year

    ICAD: U.S. Tomo Launched, Should Be 2017 Catalyst

    Strength in Detection was attributed to 3D tomo sales in Europe – management noted 7 or 8 systems were sold in Q1 – as well as from “several very large (2D) tenders.”  Management mentioned that Q1 set a new record in terms of international CAD orders.  We note that since ordering patterns can be somewhat lumpy, we have not carried that level of revenue through to our Q2 number – but we also note that management indicated interest in 3D tomo in Europe continues to solidify and, as such, we think it is reasonable to expect that product will to continue to gain traction.